{"product_id":"prta-vrio-analysis","title":"Prothena Corporation plc (PRTA): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Prothena Corporation plc (PRTA) truly built for lasting success? This VRIO analysis cuts straight to the heart of their competitive advantage, scrutinizing whether their assets are Valuable, Rare, Inimitable, and Organized for superior performance. Uncover the distilled summary of their strategic strengths and weaknesses right here, and see exactly what keeps them ahead of the curve - or where they might be exposed - by reading on below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eProthena Corporation plc (PRTA) - VRIO Analysis: First Core Capabilities \/ Resources: Protein Dysregulation Scientific Expertise\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at Prothena Corporation plc and trying to figure out what truly separates them from the pack, beyond the latest clinical trial press release. It all comes down to that deep-seated knowledge in protein dysregulation - the science that underpins their entire late-stage pipeline.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue: The Therapeutic Engine\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis expertise is definitely valuable because it lets Prothena Corporation plc target truly devastating conditions. We're talking about developing novel therapeutics for neurodegenerative diseases like Alzheimer's disease and Parkinson's disease, plus rare peripheral amyloid diseases such as ATTR amyloidosis. This isn't just academic; it's translating into tangible progress. For instance, their partner Novo Nordisk initiated the Phase 3 CLEOPATTRA trial for coramitug in ATTR amyloidosis with cardiomyopathy, which is a direct output of this core science.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: Decades in the Making\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHonestly, this specialized knowledge isn't something you can just hire for next quarter. It’s deep, specialized expertise built over decades of research, which simply isn't common across the biotech sector. While they reported $120.3 million in R\u0026amp;D expenses for the first nine months of 2025 to fuel this work, the underlying scientific insights are rare assets. It’s the institutional memory on how misfolded proteins behave.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: Tacit Knowledge Barrier\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt’s high barrier to copy this. Imitating this capability is tough because it relies heavily on accumulated tacit knowledge - the stuff scientists learn through years of trial and error - not just what’s published in a journal. You can buy the data, but you can’t buy the intuition that guides target selection for their pipeline candidates like BMS-986446 (PRX005) in Alzheimer's.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: Pipeline Alignment\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProthena Corporation plc is clearly organized around this expertise. The entire pipeline strategy, from wholly-owned assets to partnered programs with giants like Bristol Myers Squibb and Roche, flows directly from their understanding of neurological dysfunction and misfolded proteins. They are structured to exploit this knowledge base, which is why they can manage complex, late-stage trials across multiple indications simultaneously.\u003c\/p\u003e\n\u003cp\u003eHere’s a quick look at how this capability stacks up against the VRIO framework, keeping in mind their current financial footing:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eImplication for Prothena Corporation plc\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eEnables novel, high-impact therapeutic development.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eDeep, specialized expertise is scarce in the industry.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003ctd\u003eRelies on tacit, accumulated scientific insight.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003ePipeline and strategy are fully aligned to leverage it.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003ePotential for long-term differentiation if pipeline delivers.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThis expertise is what supports the market's view, even with a current net loss of $222.5 million for the first nine months of 2025. The cash position of $331.7 million at the end of Q3 2025 is what funds the continuation of this advantage.\u003c\/p\u003e\n\u003cp\u003eTo be fair, the success hinges on clinical execution, but the scientific foundation is solid. Here are some key metrics tied to this capability:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D expenses (9 months 2025): \u003cstrong\u003e$120.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eProjected full-year 2025 net cash used: \u003cstrong\u003e$170 to $178 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePipeline advancement: Roche to initiate Phase 3 for prasinezumab by end of 2025.\u003c\/li\u003e\n\u003cli\u003ePotential future value: Up to $105 million in aggregate clinical milestone payments by end of 2026 from partners.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft the Q4 2025 cash burn projection incorporating the expected year-end cash balance of approximately $298 million by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eProthena Corporation plc (PRTA) - VRIO Analysis: Second Core Capabilities \/ Resources: PRX012 Alzheimer's Program (Wholly-Owned)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Potential best-in-class, single-injection, once-monthly subcutaneous treatment for Alzheimer's disease.\u003c\/p\u003e\n\u003cp\u003eThe Alzheimer's Disease market in the 8 major markets is expected to reach \u003cstrong\u003e$19.3 billion\u003c\/strong\u003e by 2033. Approximately between \u003cstrong\u003e5% to 6%\u003c\/strong\u003e of AD patients are early-symptomatic.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High potential for a novel mechanism in a massive market, with initial Phase 1 ASCENT data expected around August 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; the specific molecule and data are unique, but the target class sees competitive entry.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High focus post-restructuring; management is prioritizing this key wholly-owned asset.\u003c\/p\u003e\n\u003cp\u003eFinancial context for prioritizing this asset:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAs of June 30, 2025, Prothena had \u003cstrong\u003e$372.3 million\u003c\/strong\u003e in cash, cash equivalents and restricted cash.\u003c\/li\u003e\n\u003cli\u003eThe company expects to end 2025 with approximately \u003cstrong\u003e$298 million\u003c\/strong\u003e (midpoint) in cash, cash equivalents, and restricted cash.\u003c\/li\u003e\n\u003cli\u003eResearch and development (R\u0026amp;D) expenses surged \u003cstrong\u003e43.2%\u003c\/strong\u003e to \u003cstrong\u003e$64.1 million\u003c\/strong\u003e in Q1 2024, primarily due to clinical trial expenses.\u003c\/li\u003e\n\u003cli\u003eNet cash used in operating and investing activities for the first six months of 2025 was \u003cstrong\u003e$99.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary (pending positive Phase 1 success).\u003c\/p\u003e\n\u003cp\u003ePhase 1 ASCENT Clinical Program Data Summary:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003ePRX012 Data Point\u003c\/td\u003e\n\u003ctd\u003eContext\/Comparison Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eParticipants Enrolled\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e228\u003c\/strong\u003e (early symptomatic AD)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDose Range Tested\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e45 mg\u003c\/strong\u003e to \u003cstrong\u003e400 mg\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmyloid PET Reduction (400mg\/Month 12)\u003c\/td\u003e\n\u003ctd\u003eMean reduction to \u003cstrong\u003e27.47 centiloids (CL)\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFDA-approved thresholds: $\\le$\u003cstrong\u003e30 CL\u003c\/strong\u003e or $\\le$\u003cstrong\u003e24.1 CL\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInjection Site Reactions (PRX012)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eARIA-E Rate (Highest Doses)\u003c\/td\u003e\n\u003ctd\u003eBetween \u003cstrong\u003e38.1%\u003c\/strong\u003e and \u003cstrong\u003e41.7%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eLeqembi: \u003cstrong\u003e13%\u003c\/strong\u003e; Lilly studies: \u003cstrong\u003e3%\u003c\/strong\u003e and \u003cstrong\u003e6%\u003c\/strong\u003e (symptomatic)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eProthena Corporation plc (PRTA) - VRIO Analysis: Third Core Capabilities \/ Resources: Coramitug ATTR-CM Program (Partnered with Novo Nordisk)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Potential first-in-class amyloid depleter for ATTR amyloidosis with cardiomyopathy (ATTR-CM).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High, as the Phase 3 CLEOPATTRA trial was initiated by Novo Nordisk by the end of 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; Novo Nordisk's backing and the asset's late-stage clinical status are significant barriers.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Leveraged through a major partner, significantly reducing Prothena's direct R\u0026amp;D cost burden.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained (due to partnership and clinical stage).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eProgram Milestones and Status:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnership\/Acquisition Date\u003c\/td\u003e\n\u003ctd\u003eJuly 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Milestones for PRTA\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$1.2 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMilestones Earned to Date (as of Nov 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$100 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 Trial Name\u003c\/td\u003e\n\u003ctd\u003eCLEOPATTRA (NCT07207811)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 Initiation Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOctober 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2 Data Presentation Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNovember 10, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan Drug Designation\u003c\/td\u003e\n\u003ctd\u003eU.S. FDA and EMA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Patient Subgroup Size (Moderate-to-Advanced)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e33%\u003c\/strong\u003e of ATTR amyloidosis patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCoramitug Program Details:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eMechanism: Potential first-in-class amyloid depleter antibody designed to target and clear non-native TTR aggregates (misTTR).\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003ePhase 1 Trial Outcome: Found to be safe and well tolerated in patients with hereditary forms of ATTR.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003ePhase 3 CLEOPATTRA Trial Objective: Evaluate the effects of coramitug versus placebo on cardiovascular outcomes in patients with ATTR-CM.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eFinancial Structure: Prothena is eligible to earn an additional clinical milestone payment when prespecified enrollment criteria are met in the Phase 3 clinical trial.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eProthena's Financial Position Supporting Organization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eQuarter-end cash, cash equivalents and restricted cash as of September 30, 2024: \u003cstrong\u003e$520.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eNet cash used in operating and investing activities for the third quarter of 2025: \u003cstrong\u003e$40.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eNet loss for the third quarter of 2025: \u003cstrong\u003e$36.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eProthena Corporation plc (PRTA) - VRIO Analysis: Fourth Core Capabilities \/ Resources: Prasinezumab Parkinson's Program (Partnered with Roche)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Potential first disease-modifying treatment for Parkinson's disease, a condition affecting 10 million people worldwide. Roche has stated peak sales potential greater than $3.5 billion (unadjusted). Phase 3 PARAISO initiation is expected by the end of 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Very high; advancing to Phase 3 in Parkinson's disease represents a significant market differentiator, especially as a potential disease-modifying therapy. The global Parkinson's disease therapeutics market was valued at USD 6.2 billion in 2024 and is projected to reach USD 13.3 billion by 2034.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; Roche's commitment and the asset's maturity are difficult for competitors to replicate quickly. The development partnership was initially agreed upon in 2013.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong validation from Roche advancing the program to the Phase 3 PARAISO trial. Prothena's financial position as of September 30, 2025, included $331.7 million in cash, cash equivalents and restricted cash, with no debt.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained.\u003c\/p\u003e\n\u003cp\u003eContextual data from prior clinical studies:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eStudy\u003c\/th\u003e\n\u003cth\u003eEndpoint\/Analysis Group\u003c\/th\u003e\n\u003cth\u003eResult Metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase IIb PADOVA (N=\u003cstrong\u003e586\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003ePrimary Endpoint (Time to confirmed motor progression)\u003c\/td\u003e\n\u003ctd\u003eHazard Ratio [\u003cstrong\u003eHR\u003c\/strong\u003e] \/ p-value\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eHR=0.84\u003c\/strong\u003e [0.69-1.01]; p=\u003cstrong\u003e0.0657\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase IIb PADOVA (N=\u003cstrong\u003e586\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eLevodopa Subgroup (\u003cstrong\u003e75%\u003c\/strong\u003e of participants)\u003c\/td\u003e\n\u003ctd\u003eHazard Ratio [\u003cstrong\u003eHR\u003c\/strong\u003e] \/ nominal p-value\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eHR=0.79\u003c\/strong\u003e [0.63-0.99]; nominal p=\u003cstrong\u003e0.0431\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase II PASADENA OLE (4-year data)\u003c\/td\u003e\n\u003ctd\u003eDelayed-start group (n=\u003cstrong\u003e94\u003c\/strong\u003e) decline in MDS–UPDRS Part III OFF state vs. PPMI (n=\u003cstrong\u003e303\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eSlower Decline Percentage\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-51%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase II PASADENA OLE (4-year data)\u003c\/td\u003e\n\u003ctd\u003eEarly-start group (n=\u003cstrong\u003e177\u003c\/strong\u003e) decline in MDS–UPDRS Part III OFF state vs. PPMI (n=\u003cstrong\u003e303\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eSlower Decline Percentage\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-65%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eCollaboration Financial Milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProthena received an upfront fee of $30 million and was promised up to a total of $600 million in future payouts from Roche upon deal signing in 2013.\u003c\/li\u003e\n\u003cli\u003eProthena has collected a total of $135 million from the Roche collaboration as of June 2025.\u003c\/li\u003e\n\u003cli\u003eA $60 million milestone payment was achieved after dosing the first patient in the Phase 2b PADOVA study.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eProthena Corporation plc (PRTA) - VRIO Analysis: Fifth Core Capabilities \/ Resources: Financial Runway and Cash Position\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides operational flexibility, with expected year-end 2025 cash of approximately \u003cstrong\u003e$298 million\u003c\/strong\u003e against a net burn of \u003cstrong\u003e$170 to $178 million\u003c\/strong\u003e. As of September 30, 2025, Prothena had \u003cstrong\u003e$331.7 million\u003c\/strong\u003e in cash, cash equivalents and restricted cash, and no debt.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many clinical-stage biotechs have less secure funding positions heading into 2026. The revised 2025 net cash burn guidance of \u003cstrong\u003e$170 to $178 million\u003c\/strong\u003e followed a corporate restructuring that included discontinuing development of birtamimab, expected to reduce annualized net cash burn by approximately \u003cstrong\u003e$96 million\u003c\/strong\u003e (midpoint).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; cash on hand is a tangible, non-imitable resource at this specific moment in time. The cash position is supported by pipeline value, including potential milestone payments.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Managed via a June 2025 restructuring to extend this runway effectively. The Company expects to convene an Extraordinary General Meeting by year-end 2025 to propose a reduction of share capital to support a potential share redemption program.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary (it depletes over time). The runway supports key upcoming milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRoche to initiate the Phase 3 PARAISO clinical trial evaluating prasinezumab for early-stage Parkinson's disease by the end of 2025.\u003c\/li\u003e\n\u003cli\u003ePotential to earn up to \u003cstrong\u003e$105 million\u003c\/strong\u003e in aggregate clinical milestone payments in 2026 related to partnered programs with Novo Nordisk and Bristol Myers Squibb.\u003c\/li\u003e\n\u003cli\u003eAs of February 13, 2025, Prothena had approximately \u003cstrong\u003e53.8 million\u003c\/strong\u003e ordinary shares outstanding.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe financial context supporting the runway is detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eValue\/Range\u003c\/th\u003e\n\u003cth\u003eReference Period\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Year-End 2025 Cash (Midpoint)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$298 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear-End 2025 Guidance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected 2025 Net Cash Burn (Operating \u0026amp; Investing)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$170 to $178 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2025 Guidance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents \u0026amp; Restricted Cash\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$331.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Used in Operating \u0026amp; Investing Activities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$140.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFirst Nine Months of 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated 2025 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$240 to $248 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2025 Guidance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated 2025 Non-Cash Share-Based Compensation\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$36 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2025 Guidance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated 2025 Non-Cash Income Tax Expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$44.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2025 Guidance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eProthena Corporation plc (PRTA) - VRIO Analysis: Sixth Core Capabilities \/ Resources: Collaboration Revenue Streams \u0026amp; Milestone Potential\n\u003c\/h2\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003ch\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/p\u003e\n\u003cp\u003eGenerates non-dilutive funding, with potential to earn up to \u003cstrong\u003e$105 million\u003c\/strong\u003e in aggregate clinical milestone payments by end of 2026 from partnered programs including PRX019 and coramitug.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003ch\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; having multiple late-stage partnered assets generating revenue is not common.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003ch\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/p\u003e\n\u003cp\u003eLow; existing contracts with Bristol Myers Squibb and others are legally binding and non-replicable. The PRX019 agreement includes an initial payment of \u003cstrong\u003e$80 million\u003c\/strong\u003e and future milestone payments up to \u003cstrong\u003e$617.5 million\u003c\/strong\u003e plus tiered royalties.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003ch\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/p\u003e\n\u003cp\u003eCollaboration revenue from Bristol Myers Squibb in Q1 2025 was \u003cstrong\u003e$2.8 million\u003c\/strong\u003e, showing active monetization. Total revenue for Q2 2025 was \u003cstrong\u003e$4.4 million\u003c\/strong\u003e, and for Q3 2025 was \u003cstrong\u003e$2.4 million\u003c\/strong\u003e, primarily from PRX019 Phase 1 clinical trial obligation performance. As of March 31, 2025, the aggregate amount of the transaction price allocated to unsatisfied performance obligations was \u003cstrong\u003e$9.5 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003ch\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/p\u003e\n\u003cp\u003eSustained (as long as partnerships remain active).\u003c\/p\u003e\n\n\u003cp\u003eKey Partnership Financial \u0026amp; Timeline Data:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eInitial Payment\/Acquisition Value\u003c\/th\u003e\n\u003cth\u003ePotential Clinical Milestones (Aggregate)\u003c\/th\u003e\n\u003cth\u003ePhase 1 Completion Est.\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBristol Myers Squibb (BMS)\u003c\/td\u003e\n\u003ctd\u003ePRX019\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$80 million\u003c\/strong\u003e (Upfront for license)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$617.5 million\u003c\/strong\u003e + royalties\u003c\/td\u003e\n\u003ctd\u003e2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovo Nordisk\u003c\/td\u003e\n\u003ctd\u003eCoramitug\u003c\/td\u003e\n\u003ctd\u003ePart of up to \u003cstrong\u003e$1.2 billion\u003c\/strong\u003e acquisition\u003c\/td\u003e\n\u003ctd\u003ePart of up to \u003cstrong\u003e$105 million\u003c\/strong\u003e aggregate potential by end of 2026\u003c\/td\u003e\n\u003ctd\u003eData expected H2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eRecent Collaboration Revenue:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ1 2025 Total Revenue: \u003cstrong\u003e$2.8 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ2 2025 Total Revenue: \u003cstrong\u003e$4.4 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Total Revenue: \u003cstrong\u003e$2.4 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eProthena Corporation plc (PRTA) - VRIO Analysis: Seventh Core Capabilities \/ Resources: Organizational Restructuring and Cost Focus\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Reduced operating costs significantly, with the June 2025 workforce reduction of \u003cstrong\u003e63%\u003c\/strong\u003e lowering the 2025 net cash burn projection.\u003c\/p\u003e\n\u003cp\u003eThe discontinuation of birtamimab development is expected to result in an approximate decrease of \u003cstrong\u003e$96 million\u003c\/strong\u003e (midpoint) in annualized net cash burn. Restructuring costs totaled \u003cstrong\u003e$32.6 million\u003c\/strong\u003e for the second quarter and first six months of 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric (FY 2025 Guidance Post-Restructuring)\u003c\/th\u003e\n\u003cth\u003eRevised Amount\u003c\/th\u003e\n\u003cth\u003ePrior Context\/Detail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce Reduction\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e63%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFrom an initial size of \u003cstrong\u003e163\u003c\/strong\u003e employees at the start of 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Burn (Operating \u0026amp; Investing Activities)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$170 to $178 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRepresents a significant reduction in operating costs.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Year-End Cash Position\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$298 million\u003c\/strong\u003e (midpoint)\u003c\/td\u003e\n\u003ctd\u003eCash, cash equivalents, and restricted cash.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$240 to $248 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncludes estimated \u003cstrong\u003e$36 million\u003c\/strong\u003e in non-cash share-based compensation expense.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; the speed and scale of the pivot to focus on remaining assets are notable.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; the specific internal decisions and associated restructuring charges of \u003cstrong\u003e$33.1 million\u003c\/strong\u003e for the first nine months of 2025 are unique to Prothena.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The Board and management executed a rapid pivot to conserve capital for key trials.\u003c\/p\u003e\n\u003cp\u003eThe focus is now directed toward:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSupporting remaining wholly owned programs.\u003c\/li\u003e\n\u003cli\u003eFulfilling obligations to partnered programs.\u003c\/li\u003e\n\u003cli\u003eAnticipated business development activities.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eKey upcoming milestones considered in the strategy include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInitial data expected in August 2025 from Phase 1 ASCENT clinical trials of wholly owned PRX012 for Alzheimer's disease.\u003c\/li\u003e\n\u003cli\u003ePotential to receive up to \u003cstrong\u003e$105 million\u003c\/strong\u003e in 2026 for clinical milestones from various partnered programs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary (a one-time efficiency gain).\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eProthena Corporation plc (PRTA) - VRIO Analysis: Eighth Core Capabilities \/ Resources: Intellectual Property Portfolio (Misfolded Protein Targets)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Proprietary rights to novel antibodies and mechanisms targeting specific pathogenic protein forms like tau and alpha-synuclein. This value is partially quantified by partnership terms, such as the $80 million upfront payment received from Bristol Myers Squibb for the exclusive global license to PRX019, with potential future milestone and royalty payments up to $617.5 million.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; patents covering novel biological targets in neurodegeneration are inherently rare assets. In Q2 2024, Prothena Corp stood in seventh position among its competitors in terms of patent grant share.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; protected by patents, making direct imitation legally impossible for competitors.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The entire R\u0026amp;D effort is built upon securing and defending this foundational IP. Organizational commitment is evidenced by financial structure, with a projected full year 2025 net cash used in operating and investing activities guidance of $168 to $175 million, supporting the advancement of these assets. As of September 30, 2025, the company maintained $331.7 million in cash, cash equivalents and restricted cash with zero debt.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained (as long as patents are in force).\u003c\/p\u003e\n\u003cp\u003eThe core intellectual property is embodied in the pipeline assets targeting misfolded proteins:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eTarget Protein\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eCurrent Stage\/Key Event\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePRX012\u003c\/td\u003e\n\u003ctd\u003eTau\u003c\/td\u003e\n\u003ctd\u003eAlzheimer's Disease\u003c\/td\u003e\n\u003ctd\u003eWholly-Owned\u003c\/td\u003e\n\u003ctd\u003ePhase 1 ASCENT clinical trials ongoing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrasinezumab\u003c\/td\u003e\n\u003ctd\u003eAlpha-synuclein\u003c\/td\u003e\n\u003ctd\u003eParkinson's Disease\u003c\/td\u003e\n\u003ctd\u003eRoche\u003c\/td\u003e\n\u003ctd\u003ePhase 3 PARAISO clinical trial initiation expected by end of 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePRX019\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eNeurodegenerative Diseases\u003c\/td\u003e\n\u003ctd\u003eBristol Myers Squibb\u003c\/td\u003e\n\u003ctd\u003ePhase 1 clinical trial initiated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey organizational focus areas tied to the IP portfolio include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe company expects to report multiple clinical readouts for PRX012 starting mid-2025 and continuing throughout the year from the ongoing Phase 1 ASCENT clinical trials.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003ePotential to earn up to $105 million in aggregate clinical milestone payments in 2026 related to the advancement of coramitug and PRX019.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eProthena has focused patent filings in the United States (US), Australia (AU), and Japan (JP).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eProthena Corporation plc (PRTA) - VRIO Analysis: Ninth Core Capabilities \/ Resources: Shareholder Capital Management Flexibility\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Proposing a capital reduction to create distributable reserves to support a potential 2026 share redemption program.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; the specific legal\/financial maneuver to enable a buyback is not a standard operational feature.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; requires specific Irish corporate structure and shareholder approval (EGM set for November 19, 2025).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Management is actively planning capital return strategies for 2026, signaling financial confidence.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary (contingent on EGM approval and 2026 execution).\u003c\/p\u003e\n\n\u003ch3\u003eGovernance and Capital Structure Mechanics\u003c\/h3\u003e\n\u003cp\u003eShareholder approval for the capital reduction was secured on \u003cstrong\u003eNovember 19, 2025\u003c\/strong\u003e, a necessary step under Irish corporate law to create distributable reserves for potential future distributions.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProposal Approval Votes In Favor: \u003cstrong\u003e37,779,052\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eProposal Approval Votes Against: \u003cstrong\u003e46,738\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eProposal Approval Abstentions: \u003cstrong\u003e45,906\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eOrdinary Shares Outstanding (as of July 25, 2025): Approximately \u003cstrong\u003e53.8 million\u003c\/strong\u003e or \u003cstrong\u003e53.83 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eBoard Recommendation for Proposal No. 1: Unanimously FOR\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eFinancial Context for Capital Management\u003c\/h3\u003e\n\u003cp\u003eThe context for the capital management flexibility is set against recent financial performance and guidance, which necessitates careful cash planning, such as the required draft 13-week cash view.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eAmount \/ Period\u003c\/td\u003e\n\u003ctd\u003eSource\/Date Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Restricted Cash (Quarter-End)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$372.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSecond Quarter 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull Year 2025 Net Cash Used in Op\/Inv Activities (Guidance)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$170 to $178 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2025 Guidance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Cash, Cash Equivalents, and Restricted Cash (Year-End 2025 Midpoint)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$298 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFull Year 2025 Guidance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrailing Twelve Months (TTM) Operating Cash Flow\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$188.04 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Statistics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrailing Twelve Months (TTM) Free Cash Flow\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$188.22 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Statistics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$582.71 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Statistics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnterprise Value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$235.38 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Statistics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe capital reduction sought to reduce capital up to the entire balance of the \u003cstrong\u003eshare premium account\u003c\/strong\u003e to facilitate future distributions.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516235047061,"sku":"prta-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/prta-vrio-analysis.png?v=1740208129","url":"https:\/\/dcf-model.com\/pt\/products\/prta-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}